Seeking Alpha

Dimitrije's  Instablog

Dimitrije
Send Message
Bachelor of Science in Business Admin and Marketing. Currently working as a private company director.
My blog:
ramblings...
  • Why invest in CEL-SCI Corp (CVM) 9 comments
    Oct 9, 2009 1:43 AM | about stocks: CVM
     
    With the amount of hype and madness this company has been getting recently it’s becoming increasing more difficult to sort thru the enormous amount of BS that is out there. Majority of the madness is coming from either not understanding what the company and its products are about or having ulterior motives for putting out information that is either biased or flat out wrong.   The fact is that majority of what you will read as of recent is simply some guys opinion and nothing more.   It’s been said over and over again that each investor should do his/her own research and due diligence when researching a stock and not rely on opinions. However when money is on the table and information is scarce—many will fall prey to the predators that lurk in the blue wide yonder that is the internet. I spend a considerable amount of time researching this company and I will post that research for everybody to make their own decisions. I am not a journalist or a blogger so don’t expect some grand insight or witty article. All I have is links to verifiable sources such as government websites and other confirmable sources not some website a 16 year old put up overnight.   
    First some basic information about the company:
     
    CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company's most advanced product, Multikine, manufactured using the company's proprietary cell culture technologies, is being developed for the treatment of cancer. Multikine is designed to target the tumor micro-metastises that are mostly responsible for treatment failure. The basic idea of Multikine is to make current cancer treatments more successful. The lead indication is advanced primary head & neck cancer. Since Multikine is not tumor specific, it may also be applicable in many other solid tumors. The Company also owns a pre-clinical technology called L.E.A.P.S., Ligand Epitope Antigen Presentation System. The lead product derived from this technology is the CEL-1000 peptide which has shown protection in animals against herpes, malaria and cancer. With the help of government grants and US Army and US Navy collaborations, CEL-1000 is now being tested against viral encephalitis, West Nile Virus, SARS, Vaccinia, Smallpox, herpes, malaria and other agents. If the bio-terrorism tests are successful, CEL-SCI is likely to push CEL-1000 for potential bio-terrorism disease indications to gain accelerated approval.
     
    The company holds several patents in the field and has several in pre-grant status. See the links below from United States Patent and Trademark Office .
     
    The company has two products. 
    Multikine®, CEL-SCI's flagship cancer product, is the first immunotherapeutic agent being developed as a first-line standard of care cancer treatment. Multikine® is a different kind of weapon in the fight against cancer; one that harnesses our body's natural ability to fight tumors.
    Multikine® is also the first of a new class of cancer immunotherapy drugs. It is the first comprehensive immunotherapy and the first Immune SIMULATOR.
    L.E.A.P.S.™ is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S.™ compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.
    This new technology has been shown in several animal models to preferentially direct immune response to a cellular (e.g. T-cell), humoral (antibody) or mixed pathway. Any disease for which antigenic epitope sequences have been identified, such as: infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer’s) are potential candidates for this technology platform.
     
     
    Since I have a very basic understanding of biochemistry and by no means am I an expert, I’ll attempt to explain what they are currently used for. Both of the drugs are immunotherapy drugs—their role is to help the immune system during treatment not flat out cure the disease. There has been a number of posts and blogs about supposed statements that company has made regarding what these drugs do.
     For example many have the wrong impression that LEAPS-H1N1 treatment is a vaccine for the swine flu and have created their arguments around this point; when the facts are that the drug is not a vaccine rather its role is to help the patients who already have the H1N1 to recover. Personally I think this is the right approach since the virus has shown signs of mutation and resistance to certain conventional treatments and the market is already swamped with many other companies developing vaccines.  Read more about the LEAPS treatment
    Multikine has essentially the same role expect in cancer cells.  Recently talked about use is in reducing the size of the tumor in head and neck cancer patients so that the doctors can performs surgeries easier and with the least amount of cosmetic damage.  It has also uses in treating cervical cancer. 
    In addition Multikine has been approved by the FDA for phase III trials. Multikine has also been granded the Orphan Status by the FDA.
     
    In addition CEL-SCI scientists will present a paper regarding their CEL-2000 (rheumatoid arthritis treatment based on L.E.A.P.S) in upcoming ACR/ARHP 2009.
     
     
    Some information about the much talked about cold fill facility
    Address:
     
     
    Hopefully this has helped you better understand the company and what they are trying to accomplish. Should you invest? The choice is yours. I know I am and so are the company insiders…
     
     
     Disclosure: Long on CVM
     
Back To Dimitrije's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (9)
Track new comments
  • JATIB
    , contributor
    Comment (1) | Send Message
     
    Thank you very much Mr Dimitrije for your article "Why Invest in CVM". I appreciate all the information you put out, I strongly believe your data is excellent, and I am glad I invested in CVM. I was feeling kind of disappointed because of all the negative stuff, but after reading your article I feel more at ease and confident I did the right thing.
    Thank you sir for taking the time to help us out.
    Sincerely,
    Jose R Jatib
    emmayjose@hotmail.com
    9 Oct 2009, 05:25 AM Reply Like
  • User 498085
    , contributor
    Comment (1) | Send Message
     
    you look like Mr Bean
    9 Oct 2009, 07:57 AM Reply Like
  • Biohitechinvestor
    , contributor
    Comments (2) | Send Message
     
    I really don't know who to believe. The company is too vague here and that is causing concern and disbelief. I sold after buying at $.49 hoping it see the stock rise to $5 in the near future. I made my money but expected more from what I thought was a company on its way up again. Now that I am sitting on the side, I shall wait and perhaps get back in if it reaches $2 knowing that the move is up and not down anymore. Technically speaking we can go under $1 as well in the next couple of months if not sooner. Meanwhile, I sit and wait, not willing to take a chance on just too much speculation and guessing.
    Biohitechinvestor
    9 Oct 2009, 08:00 AM Reply Like
  • User 498173
    , contributor
    Comment (1) | Send Message
     
    Greetings from a German Investor, living in Germany!
    ThanxXXL for this excellent information you have provided.
    Your information is already circulating in the German Internet.
    To me, things are a bit out of the cloud, after reading,
    what you have said.
    I have become aware of this Share, by reading a German
    Stock-Market-Report.
    In this report, this stock was highly recommended, so,
    I purchased.
    By now, I have lost some 35% on this investment.
    I was just about to sell, but for now, after you article,
    I will give a new change to this company and will stay
    invested.
    Hope we will see a U-Turn soon.
    Again, Thank you very much!
    Jeff K. from Germany
    9 Oct 2009, 10:32 AM Reply Like
  • M. E. Garza
    , contributor
    Comments (123) | Send Message
     
    Great work! Thanks for sharing your info with everyone.
    9 Oct 2009, 10:34 AM Reply Like
  • User 395248
    , contributor
    Comment (1) | Send Message
     
    Great Post :)
    10 Oct 2009, 06:13 PM Reply Like
  • dam dam
    , contributor
    Comments (5) | Send Message
     
    Why street sick ass is killing us when we have so much of information(facts), if some editor gives wrong information about company who will monitor and controls this kind (street.com) manipulation.

     

    Thanks for information and it is great to read, we still think this guys make it and helps everybody.

     

    sree
    10 Oct 2009, 08:59 PM Reply Like
  • homeschooled
    , contributor
    Comments (17) | Send Message
     
    The fundamentals and direction alone are such that if one target is reached the stock will fly to at least $20. If all are attained then money will look cheap compared to the value of this company. The quality of human life weighs in the balance. Considering to invest or not should be obvious. Weigh the benefit of a research company against the alternatives, perhaps a war stock like HAL We'd best put our money where it can do some good! As a humanitarian my choice is obvious...
    28 Oct 2009, 08:04 PM Reply Like
  • User 486776
    , contributor
    Comment (1) | Send Message
     
    Good synopsis of the company. A more comprehensive view of the totality that CVM is.

     

    bobbydee11@yahoo.com
    6 Nov 2009, 08:40 AM Reply Like
Full index of posts »
Latest Followers

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.